BMO Capital analyst Alex Arfaei reiterated an Underperform rating and $78 price target on Abbvie (NYSE: ABBV) saying the California ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE